220 related articles for article (PubMed ID: 25940823)
21. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
Zembutsu H
Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
[TBL] [Abstract][Full Text] [Related]
22. Is personalized medicine a dream or a reality?
Morse BL; Kim RB
Crit Rev Clin Lab Sci; 2015 Feb; 52(1):1-11. PubMed ID: 25181036
[TBL] [Abstract][Full Text] [Related]
23. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
[TBL] [Abstract][Full Text] [Related]
24. The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes.
Johänning J; Kröner P; Thomas M; Zanger UM; Nörenberg A; Eichelbaum M; Schwab M; Brauch H; Schroth W; Mürdter TE
Arch Toxicol; 2018 Mar; 92(3):1099-1112. PubMed ID: 29285606
[TBL] [Abstract][Full Text] [Related]
25. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC
J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721
[TBL] [Abstract][Full Text] [Related]
26. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M; Komagata S; Fujiki Y; Kanada Y; Ebi H; Itoh K; Mukai H; Yokoi T; Minami H
Pharmacogenet Genomics; 2007 Jun; 17(6):431-45. PubMed ID: 17502835
[TBL] [Abstract][Full Text] [Related]
28. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.
Barginear MF; Jaremko M; Peter I; Yu C; Kasai Y; Kemeny M; Raptis G; Desnick RJ
Clin Pharmacol Ther; 2011 Oct; 90(4):605-11. PubMed ID: 21900890
[TBL] [Abstract][Full Text] [Related]
29. Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.
Henderson SL; Teft WA; Kim RB
BMC Cancer; 2016 May; 16():304. PubMed ID: 27169677
[TBL] [Abstract][Full Text] [Related]
30. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
31. Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes.
Watanabe M; Watanabe N; Maruyama S; Kawashiro T
Drug Metab Pharmacokinet; 2015 Oct; 30(5):325-33. PubMed ID: 26423799
[TBL] [Abstract][Full Text] [Related]
32. Effects of CYP induction by rifampicin on tamoxifen exposure.
Binkhorst L; van Gelder T; Loos WJ; de Jongh FE; Hamberg P; Moghaddam-Helmantel IM; de Jonge E; Jager A; Seynaeve C; van Schaik RH; Verweij J; Mathijssen RH
Clin Pharmacol Ther; 2012 Jul; 92(1):62-7. PubMed ID: 22617226
[TBL] [Abstract][Full Text] [Related]
33. Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites.
Chen Y; Marcath LA; Eliassen FM; Lende TH; Soiland H; Mellgren G; Helland T; Hertz DL
J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34199712
[TBL] [Abstract][Full Text] [Related]
34. Tamoxifen and CYP 2D6 inhibitors: caution.
Prescrire Int; 2011; 20(118):182-4. PubMed ID: 21751753
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data.
Kruger B; Shamley D; Soko ND; Dandara C
Clin Transl Sci; 2024 Mar; 17(3):e13761. PubMed ID: 38476074
[TBL] [Abstract][Full Text] [Related]
36. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.
Binkhorst L; Kloth JSL; de Wit AS; de Bruijn P; Lam MH; Chaves I; Burger H; van Alphen RJ; Hamberg P; van Schaik RHN; Jager A; Koch BCP; Wiemer EAC; van Gelder T; van der Horst GTJ; Mathijssen RHJ
Breast Cancer Res Treat; 2015 Jul; 152(1):119-128. PubMed ID: 26050156
[TBL] [Abstract][Full Text] [Related]
37. Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts.
Gong IY; Teft WA; Ly J; Chen YH; Alicke B; Kim RB; Choo EF
Breast Cancer Res Treat; 2013 May; 139(1):61-9. PubMed ID: 23605084
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetics of endocrine therapy for breast cancer.
Higgins MJ; Stearns V
Annu Rev Med; 2011; 62():281-93. PubMed ID: 21226615
[TBL] [Abstract][Full Text] [Related]
40. Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies.
Coller JK
Clin Exp Pharmacol Physiol; 2003 Nov; 30(11):845-8. PubMed ID: 14678248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
